How Ovarian Disorders Accelerate Brain Aging Through Hormonal Imbalance

Women with ovarian disorders face not only fertility challenges but a significantly elevated risk of cognitive decline, mood disorders, and neurodegenerative disease later in life. This 2025 mini-review from Brown University and Women and Infants Hospital synthesizes current evidence linking HPO axis imbalance to brain aging, arguing that the field has been too narrowly focused on estrogen replacement while neglecting the roles of gonadotropins and progesterone.

The HPO axis operates as a tightly regulated endocrine feedback loop: GnRH from the hypothalamus drives pituitary release of FSH and LH, which stimulate ovarian follicles to produce estradiol and progesterone. These sex steroids then feed back to suppress further gonadotropin release. In ovarian disorders—menopause, POI, and PCOS—this balance is disrupted in distinct but overlapping ways. Menopause and POI are characterized by high FSH and LH alongside low estradiol and progesterone. PCOS presents with high LH, hyperandrogenism, and high AMH, with inconsistent ovulation leading to progesterone deficiency and relative estrogen excess.

The review details how estradiol exerts well-documented neuroprotective effects through estrogen receptors in the brain, supporting synaptic plasticity, reducing amyloid-beta accumulation, and modulating neuroinflammation. However, clinical trials of estrogen-only hormone replacement therapy have failed to reduce dementia risk in women over 65, suggesting a critical window of intervention and pointing to additional mechanisms. Elevated circulating LH has been shown to promote tau phosphorylation and amyloid-beta production, directly implicating gonadotropin excess—not just hormone deficiency—in neurodegeneration. Similarly, high FSH levels correlate with accelerated bone loss and metabolic dysfunction, with emerging evidence of direct FSH receptor signaling in the brain.

Systemic inflammation emerges as a key secondary driver. Conditions like PCOS generate chronic low-grade inflammation through oxidative stress and mitochondrial dysfunction in granulosa cells, reducing steroidogenesis and embryo quality. POI has similarly been associated with low-grade chronic inflammation that accelerates aging phenotypes. The review notes that endometriosis patients are twice as likely to experience mental disorders, and even asymptomatic cases show structural brain alterations, suggesting hormonal and inflammatory mechanisms beyond pain alone.

The authors call for multisystem experimental models that treat each HPO axis component—estradiol, progesterone, FSH, and LH—as individual effectors on neuronal health, rather than conflating their effects. They advocate for research into gonadotropin-targeted therapies and better characterization of the perimenopausal window as a critical intervention period, before irreversible brain changes solidify.